Richard Bryce, MBChB, MRCGP, MFPM
Senior Vice President, Clinical Research & Development
Dr. Bryce joined Puma Biotechnology as Senior Vice President, Clinical R&D in June 2012. From 2008 to 2012, he was employed at Onyx Pharmaceuticals where, as clinical lead, he oversaw the sorafenib Phase II breast and colorectal cancer programs and the carfilzomib Phase III multiple myeloma program. Previous appointments include International Medical Leader at Roche for Xeloda® in breast cancer, and senior positions at ICON Clinical Research, ILEX and Scotia Pharmaceuticals, where he was the lead clinician on successful registration studies for Campath® in CLL and multiple sclerosis, and Foscan®-PDT for squamous cell head and neck cancer.
Dr. Bryce received his BSc (Medical Sciences) and MBChB degrees from the University of Edinburgh, Scotland, in 1978 and 1981. Postgraduate board certifications include those from the Royal College of General Practitioners of the UK and Royal College of Physicians (Faculty of Pharmaceutical Medicine).
Dr. Bryce is a member of the American Society of Clinical Oncology, American Society of Hematology and the European Society of Medical Oncology.
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024